EXCLUSIVE: A new industry body for Australia’s medicinal cannabis industry, the Australian Medicinal Cannabis Association (AMCA), has launched. 

The registered not-for-profit association will work to improve patient access to high-quality, affordable medical cannabis and speak for patients, health care professionals, researchers, cultivators, manufacturers and exporters.

Join the Cannabiz revolution

Want to stay ahead of the cannabis curve with the latest local and international news, analysis and intelligence and access to Australia's legal cannabis industry?

This article is included with our Premium subscription.

AMCA is chaired by cannabis campaigner Lucy Haslam, with scientist and lawyer Teresa Nicoletti as company secretary, Gail Wiseman as general manager and registered nurse Rita Martin as deputy chair. 

The AMCA board covers a broad spectrum of the industry including manufacturing, legal, nursing, scientific research and public relations. These include consultant emergency physician David Caldicott; Ogilvy PR group managing director Leon Beswick; research fellow at NICM Health Research Institute Justin Sinclair; chief operating officer of the Australian Natural Therapeutics Group James Gaskell; and associate professor and program director at the Undergraduate Pharmacy at the University of Sydney Nial Wheate.

Speaking to Cannabiz about the launch, Teresa Nicoletti said AMCA represents the broad interests of the industry: “It’s not just about industry players, companies that have a vested interest in setting up medicinal cannabis businesses and have profitability as the goal,” she said. “We look at it more broadly because to have a viable industry, it involves a number of stakeholders including doctors, patients, nurses and caregivers.”

Teresa Nicoletti - Cannabis Australia - Cannabiz
AMCA company secretary Teresa Nicoletti

AMCA is a not-for-profit, and will initially be funded by memberships, with plans to eventually expand into training and events. “One of the big gaps in medicinal cannabis is that there is insufficient education,” said Nicoletti. “There needs to be a conversation, but that conversation needs to include education, to remove the stigma that still exists and the reticence that many doctors still have in prescribing it.”

When it comes to marketing cannabis, Nicoletti said the industry is hamstrung by the very strict rules on what you can and can’t say about medicinal cannabis. She said: “There’s a fine line between talking about medicinal cannabis for educational purposes and talking about medicinal cannabis more in a promotional context. 

“That’s an important distinction, because if it’s an educational context, it’s permissible. But if it’s then turning into a more promotional context, it’s not.”